Neurokinin 3 receptor antagonism for menopausal hot flashes.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 37541194.
- Also identified by DOI 10.1016/j.cell.2023.07.011.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Menopausal hot flashes are common and debilitating. Menopausal Hormone Therapy (MHT) is effective for hot flashes but has risks and side effects that limit its use. NK3 receptor antagonism has emerged as a novel therapeutic strategy, leading to the recent FDA approval of fezolinetant, a first-in-class nonhormonal treatment for menopausal hot flashes. To view this Bench to Bedside, open or download the PDF.
Medical subject headings
- Hot Flashes
- Menopause
- Receptors, Neurokinin-3
- Thiadiazoles